Claudia J Woloshchuk1, Katharine H Nelson2, Kenner C Rice3, Anthony L Riley4. 1. Psychopharmacology Laboratory, Center for Behavioral Neuroscience, American University, 4400 Massachusetts Ave, NW Washington, D.C. 20016, USA. Electronic address: cw2606a@student.american.edu. 2. Psychopharmacology Laboratory, Center for Behavioral Neuroscience, American University, 4400 Massachusetts Ave, NW Washington, D.C. 20016, USA. 3. Molecular Targets and Medications Discovery Branch, National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 20892, USA. 4. Psychopharmacology Laboratory, Center for Behavioral Neuroscience, American University, 4400 Massachusetts Ave, NW Washington, D.C. 20016, USA. Electronic address: alriley@american.edu.
Abstract
BACKGROUND: Drug use is thought to be a balance of the rewarding and aversive effects of drugs. Understanding how various factors impact these properties and their relative balance may provide insight into their abuse potential. In this context, the present study attempted to evaluate the effects of drug history on the aversive effects of 3,4-methylenedioxypyrovalerone (MDPV), one of a variety of synthetic cathinones (collectively known as "bath salts"). METHODS: Different groups of male Sprague-Dawley rats were exposed to either vehicle or MDPV (1.8mg/kg) once every fourth day for five total injections prior to taste avoidance conditioning in which a novel saccharin solution was repeatedly paired with either vehicle, MDPV (1.8mg/kg), the related psychostimulant cocaine (18mg/kg) or the emetic lithium chloride (LiCl) (13.65mg/kg). RESULTS: In animals pre-exposed to vehicle, all three drugs induced significant and comparable taste avoidance relative to animals injected with vehicle during conditioning. MDPV pre-exposure attenuated the avoidance induced by both MDPV and cocaine (greater attenuation for MDPV than cocaine), but had no effect on that induced by LiCl. CONCLUSIONS: These findings suggest that a history of MDPV use may reduce or attenuate MDPV and cocaine's (but not LiCl's) aversive effects. The implications for such changes in MDPV's aversive effects to its potential use and abuse were discussed.
BACKGROUND: Drug use is thought to be a balance of the rewarding and aversive effects of drugs. Understanding how various factors impact these properties and their relative balance may provide insight into their abuse potential. In this context, the present study attempted to evaluate the effects of drug history on the aversive effects of 3,4-methylenedioxypyrovalerone (MDPV), one of a variety of synthetic cathinones (collectively known as "bath salts"). METHODS: Different groups of male Sprague-Dawley rats were exposed to either vehicle or MDPV (1.8mg/kg) once every fourth day for five total injections prior to taste avoidance conditioning in which a novel saccharin solution was repeatedly paired with either vehicle, MDPV (1.8mg/kg), the related psychostimulant cocaine (18mg/kg) or the emetic lithium chloride (LiCl) (13.65mg/kg). RESULTS: In animals pre-exposed to vehicle, all three drugs induced significant and comparable taste avoidance relative to animals injected with vehicle during conditioning. MDPV pre-exposure attenuated the avoidance induced by both MDPV and cocaine (greater attenuation for MDPV than cocaine), but had no effect on that induced by LiCl. CONCLUSIONS: These findings suggest that a history of MDPV use may reduce or attenuate MDPV and cocaine's (but not LiCl's) aversive effects. The implications for such changes in MDPV's aversive effects to its potential use and abuse were discussed.
Authors: Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Tobin J Dickerson; Michael A Taffe Journal: Psychopharmacology (Berl) Date: 2015-05-01 Impact factor: 4.530
Authors: L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti Journal: Br J Pharmacol Date: 2013-01 Impact factor: 8.739
Authors: Lucas R Watterson; Peter R Kufahl; Natali E Nemirovsky; Kaveish Sewalia; Megan Grabenauer; Brian F Thomas; Julie A Marusich; Scott Wegner; M Foster Olive Journal: Addict Biol Date: 2012-07-11 Impact factor: 4.280
Authors: Heather E King; Alison Wakeford; William Taylor; Bradley Wetzell; Kenner C Rice; Anthony L Riley Journal: Pharmacol Biochem Behav Date: 2015-07-26 Impact factor: 3.533
Authors: Lucas R Watterson; Lauren Hood; Kaveish Sewalia; Seven E Tomek; Stephanie Yahn; Craig Trevor Johnson; Scott Wegner; Bruce E Blough; Julie A Marusich; M Foster Olive Journal: J Addict Res Ther Date: 2012-12-01
Authors: R López-Arnau; M A Luján; L Duart-Castells; D Pubill; J Camarasa; O Valverde; E Escubedo Journal: Br J Pharmacol Date: 2017-04-06 Impact factor: 8.739
Authors: Katharine H Nelson; Briana J Hempel; Matthew M Clasen; Kenner C Rice; Anthony L Riley Journal: Pharmacol Biochem Behav Date: 2017-04-17 Impact factor: 3.533
Authors: Katharine H Nelson; Hayley N Manke; Jacob M Bailey; Anna Vlachos; Karina J Maradiaga; Shihui Huang; Tania D Weiss; Kenner C Rice; Anthony L Riley Journal: Pharmacol Biochem Behav Date: 2021-10-08 Impact factor: 3.533
Authors: Katharine H Nelson; Raul López-Arnau; Briana J Hempel; Peter To; Hayley N Manke; Madeline E Crissman; Matthew M Clasen; Kenner C Rice; Anthony L Riley Journal: Psychopharmacology (Berl) Date: 2018-10-17 Impact factor: 4.530
Authors: William S Hyatt; Michael D Berquist; Neha M Chitre; Lauren N Russell; Kenner C Rice; Kevin S Murnane; William E Fantegrossi Journal: Behav Pharmacol Date: 2019-10 Impact factor: 2.277
Authors: William S Hyatt; Caitlin E Hirsh; Lauren N Russell; Neha M Chitre; Kevin S Murnane; Kenner C Rice; William E Fantegrossi Journal: Behav Pharmacol Date: 2020-06 Impact factor: 2.277
Authors: Samantha J McClenahan; Chad M Kormos; Melinda Gunnell; Michael D Hambuchen; Pamela Lamb; Frank Ivy Carroll; Anita H Lewin; Eric C Peterson; Samuel Michael Owens Journal: Vaccine Date: 2019-10-16 Impact factor: 3.641